Itch: Scratching more than the surface

QJM: An International Journal of Medicine

Volumn 96, Issue 1, 2003, Pages 7-26

  Twycross, R ^a   Greaves, M W ^b   Handwerker, H ^c   Jones, E A ^d   Libretto, S E ^e   Szepietowski, J C ^f   Zylicz, Z ^g,h  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e Janssen Cilag Ltd   (United Kingdom)

^f WROCLAW MEDICAL UNIVERSITY   (Poland)

^g Hospice Rozenheuvel   (Netherlands)

^h NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA ALKYL ANDROGEN; ACETYLCHOLINE; ACETYLSALICYLIC ACID; ANDROGEN; ANTIHISTAMINIC AGENT; ANTIPRURITIC AGENT; BENZOCAINE; CALAMINE; CAPSAICIN; CIMETIDINE; COLESTYRAMINE; CORTICOSTEROID; CROTAMITON; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; INDOMETACIN; LIDOCAINE; LOCAL ANESTHETIC AGENT; MENTHOL; MIRTAZAPINE; OPIATE; OPIATE ANTAGONIST; PAROXETINE; PHENOL; POLIDOCANOL; RIFAMPICIN; TETRACAINE; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BURNING SENSATION; CHOLESTASIS; CONTACT DERMATITIS; DERMATITIS; DRUG ABSORPTION; DYSPHORIA; HALLUCINATION; HEART ARRHYTHMIA; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSECT BITE; LIVER DYSFUNCTION; MECHANICAL STIMULATION; MEDIATOR; MULTIPLE SCLEROSIS; NAUSEA; NERVE FIBER C; NERVE TRACT; NEUROPATHY; PARANEOPLASTIC NEUROPATHY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN DISEASE; SKIN SURFACE; SYSTEMIC DISEASE; ULTRAVIOLET B RADIATION; UREMIA; URTICARIA;

EID: 0037256736     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/hcg002     Document Type: Review

References (211)

1. Haffenreffer S. (1660) From: Rothman S. Physiology of itching. Physiological Reviews 1941; 21:357-81.
2. Taylor B, Wadsworth J, Wadsworth M, Peckham C. Changes in the reported prevalence of childhood eczema since the 1939-45 war. Lancet 1984; 2:1255-7.
3. Rea JN, Newhouse ML, Halil T. Skin disease in Lambeth: a community study of prevalence and the use of medical care. Br J Prevent So Med 1976; 30:107-14.
4. Handwerker HO, Forster C, Kirchhoff C. Discharge patterns of human C-fibers induced by itching and burning stimuli. Neurophysiol 1991; 66:307-15.
5. Schmelz M, Michael K, Weidner C, Schmidt R, Torebjork HE, Handwerker HO. Which nerve fibers mediate the axon reflex flare in human skin? Neuroreport 2000; 11:645-8.
6. Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjork HE. Specific C-receptors for itch in human skin. Neurosci 1997; 17:8003-8.
7. Lerner EA. Chemical mediators of itching. In: Berhard J, editor. Itch: Mechanisms and Management of Pruritus. New York, McGraw-Hill, 1994:23-35.
8. Hagernark O. Itch mediators. Semin Dermatol 1995; 14:271-6.
9. Hagermark O. Influence of antihistamines, sedatives, and aspirin on experimental itch. Acta Dermato-Venereologica (Stockh) 1973; 53:363-8.
10. 1 antagonist effects on histamine induced pruritus and allokinesis. Pain 1997; 73:239-43.
11. Bickford RG. Experiments relating to the itch sensation, its peripheral mechanism, and central pathways. Clin Sci 1938; 3:377-86.
12. Simone DA, Alreja M, LaMotte RH. Psychophysical studies of the itch sensation and itchy skin ('alloknesis') produced by intracutaneous injection of histamine. Somatosens Motor Res 1991; 8:271-9.
13. Liddell K. Post-herpetic pruritus. Br Med J 1974; 4:165.
14. Layton AM, Cotterill JA. Notalgia paraesthesia-report of three cases and their treatment. Clin Exp Dermatol 1991; 16:197-8.
15. Cockerall CJ. The itches of HIV infection and AIDS. In: Bernhard J, editor. Itch: Mechanisms and Management of Pruritus. New York, McGraw-Hill, 1994:347-65.
16. Andreev VC, Petkov I. Skin manifestations associated with tumours of the brain. Br J Dermatol 1975; 92:675-8.
17. King CA, Huff FJ, Jorizzo JL. Unilateral neurogenic pruritus: paroxysmal itching associated with central nervous system lesions. Ann Intern Med 1982; 97:222-3.
18. Massey EW. Unilateral neurogenic pruritus following stroke. Stroke 1984; 15:901-3.
19. Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology 1999; 29:1003-6.
20. Borgeat A, Stimemann H-R. Ondansetron is effective to treat spinal or epidural morphine-induced pruritus. Anesthesiology 1999; 90:432-6.
21. Parker F. Skin diseases. In: Wyngaarden J, Smith L, eds. Textbook of Medicine, 18th edn. Philadelphia, WB Saunders, 1988:2300-53.
22. Schmelz M, Luz O, Averbeck B, Bickel A. Plasma extravasation and neuropeptide release in human skin as measured by intradermal microdialysis. Neurosci Letters 1997; 230:117-20.
23. Weidner C, Klede M, Rukwied R, Lischetzki G, Neisius U, Skov PS, Petersen LJ, Schmelz M. Acute effects of substance P and calcitonin gene-related peptide in human skin: a microdialysis study. J Invest Dermatol 2000; 115:1015-20.
24. 2-receptor blocking agent. Br J Clin Pharmacol 1977; 4:367.
25. 2 antihistamine therapy in chronic urticaria. Arch Dermatol 1981; 117:404-7.
26. Greaves MW. Urticaria: new molecular insights and treatments. The Parkes Weber Lecture 1991. J Roy Coll Physicians London 1992; 26:199-203.
27. Krause L, Shuster S. Mechanisms of action of antipruritic drugs. Br Med J 1983; 287:1199-200.
28. Berth-Jones J, Graham-Brown RAC. Failure of terfenadine in relieving the pruritus of atopic dermatitis. Br J Dermatol 1989; 121:635-7.
29. Gittlen SD, Schulman ES, Maddrey WC. Raised histamine concentrations in chronic cholestatic liver disease. Gut 1990; 31:96-9.
30. Mettang T, Fritz P, Weber J, Machleidt C, Hubel E, Kuhlmann V. Uremic pruritus in patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD): the role of plasma histamine and skin mast cells. Clin Nephrol 1990; 34:136-41.
31. Kaliner M, Shelmar J, Ottesen E. Effects of infused histamine; correlation of plasma histamine levels and symptoms. J Allergy Clin Immunol 1982; 62:283-9.
32. Greaves MW, Shuster S. Responses of skin blood vessels to bradykinin, histamine and 5-hydroxytryptamine. J Physiol 1967; 193:255-67.
33. Stahle-Backdahl M, Hagermark O, Lins L-E. The sensitivity of uremic and normal human skin to histamine. Acta Dermato-Venereologica (Stockh) 1988; 68:230-5.
34. Rukwied R, Lischetzki G, McGlone F, Heyer G, Schmelz M. Mast cell mediators other than histamine induce pruritus in atopic dermatitis: a dermal microdialysis study. Br J Dermatol 2000; 142:1-8.
35. Heyer GR, Hornstein OP. Recent studies of cutaneous nociception in atopic and non-atopic subjects. J Dermatol 1999; 26:77-86.
36. Hagermark O. Peripheral and central mediators of itch. Skin Pharmacol 1992; 5:1-8.
37. 3 receptor antagonist (tropisetron) is dependent on mast cell depletion: an experimental study. Exp Dermatol 1999; 8:254-60.
38. Kyriakides K, Hussain SK, Hobbs GJ. Management of opioid-induced pruritus: a role for 5HT antagonists? Br J Anaesthesia 1999; 82:439-41.
39. Greaves MW, McDonald-Gibson W. Itch: role of prostaglandins. Br Med J 1973; 3:608-9.
40. 2 and a prostaglandin endoperoxide analog. J Investigative Dermatology 1977; 69:527-30.
41. Jackson N, Burt D, Crocker J, Boughton B. Skin mast cells in polycuthaemia vera: relationship to the pathogenesis and treatment of pruritus. Br J Dermatol 1987; 116:21-9.
42. Daly BM, Shuster S. Effect of aspirin on pruritus. Br Med J 1986; 293:907.
43. Smith KJ, Skelton HG, Yeager J. Pruritus in HIV-1 disease: therapy with drugs which may modulate the pattern of immune dysregulation. Dermatology 1997; 195:353-8.
44. Wahlgren CF, Linder MT, Hagermark O. Itch and inflammation induced by intradermally injected interleukin-2 in atopic dermatitis patients and healthy subjects. Arch Dermatol Res 1995; 287:572-80.
45. Wahlgren CF, Scheynius A, Hagermark O. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Dermatolo-Venereologica (Stockh) 1990; 70:323-9.
46. Hagermark O, Wahlgren CF. Some methods for evaluating clinical itch and their application for studying pathophysiological mechanisms. J Dermatol Sci 1992; 4:55-62.
47. Tsai JC, Feingold KR, Crumrine D, Wood LC, Grunfeld C, Elias PM. Permeability barrier disruption alters the localization and expression of TNF alpha/protein in the epidermis. Arch Dermatol Res 1994; 286:242-8.
48. Brain SD. New feelings about the role of sensory nerves in inflammation. Nature Med 2000; 6:134-5.
49. Steinhoff M, Vergnolle N, Young SH, Tognetto M, Amadesi S, Ennes HS, Trevisani M, Hollenberg MD, Wallace JL, Caughey GH, Mitchell SE, Williams LM, Geppetti P, Mayer EA, Bunnett NW. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nature Med 2000; 6:151-8.
50. Jorizzo JL, Coutts AA, Eady RAJ, Greaves MW. Vascular responses to injection of substance P and mechanism of action. Eur J Pharmacol 1983; 87:67-76.
51. Wallengren J, Hakanson R. Effects of substance P, neurokinin A and calcitonin gene-related peptide in human skin and their involvement in sensory nerve-mediated responses. Eur J Pharmacol 1987; 143:267-73.
52. 1 tachykinin receptors in mice. J Pharmacol Exp Therapeut 1998; 286:1140-5.
53. Caughey GH, Leidig F, Viro NF, Nadel JA. Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. J Pharmacol Exp Therapeut 1988; 244:113-17.
54. Ellis CN, Berberian B, Sulica VI, Dodd WA, Jarratt MT, Katz HI, Prawer S, Krueger G, Rex IH, Wolf JE. A double-blind evaluation of topical capsaicin in pruritic psoriasis. J Am Acad Dermatol 1993; 29:438-42.
55. Green BG, Shaffer GS. The sensory response to capsaicin during repeated topical exposures: differential effects on sensations of itching and pungency. Pain 1993; 53:323-34.
56. Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR. Topical capsaicin in humans: parallel loss of epidermal nerve fibres and pain sensation. Pain 1999; 81:135-45.
57. 2 in the human skin. Br J Dermatol 1992; 126:111-17.
58. McCormack HM, deL'Horne DJ, Sheather S. Clinical applications of visual analogue scales: a critical review. Psycholog Med 1988; 18:1007-19.
59. Bergasa NV, Alling DW, Talbot T. Assessment of the pruritus of cholestasis: an appraisal of the visual analogue score. Hepatology 1990; 12:887 (abstract 198).
60. Wahlgren CF. Itch and atopic dermatitis: clinical and experimental studies. Acta Dermato-Venereologica (Stockh) 1991; 165:1-53.
61. Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, Schmitt JM, Walker EC, Jones EA. Effects of naloxone infusions in patients with the pruritus of cholestasis. Ann Intern Med 1995; 123:161-7.
62. Talbot TL, Schmitt JM, Bergasa NV, Jones EA, Walker EC. Application of piezo film technology for the quantitative assessment of pruritus. Biomed Instrument Technol 1991; 25:400-3.
63. Molenaar HAJ, Oosting J, Jones EA. Improved device for measuring scratching activity in patients with pruritus. Med Biol Eng Comput 1998; 36:220-4.
64. Ghadially R, Brown BE, Hanley K, Reed JT, Feingold KR, Elias PM. Decreased epidermal lipid synthesis accounts for altered barrier function in aged mice. J Invest Dermatol 1996; 106:1064-9.
65. Bergasa NV, Jones EA. The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids. Gastroenterology 1995; 108:1582-8.
66. Jones EA, Bergasa NV. The pruritus of cholestasis: from bile acids to opiate agonists. Hepatology 1990; 11:884-7.
67. Thornton JR, Losowksy MS. Opioid peptides and primary biliary cirrhosis. Br Med J 1988; 297:1501-4.
68. Swain MG, Rothman RB, Xu H, Vergalla J, Bergasa NV, Jones EA. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 1992; 103:630-5.
69. Bergasa NV, Sabol SL, Yound WS, Kleiner DE, Jones EA. Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol 1995; 268:G346-54.
70. Bergasa NV, Thomas DA, Vergalla J, Turner ML, Jones EA. Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys. Life Sci 1993; 53:1253-7.
71. Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EF, Baker BL, Korenman JC, Park Y, Hoofnagle JH, Jones EA. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992; 102:544-9.
72. Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, Jenkins JB, Jones EA. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998; 27:679-84.
73. Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 1999; 41:431-4.
74. Jones EA, Dekker LRC. Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterology 2000; 118:431-2.
75. Jones EA, Neuberger J, Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. Q J Med 2002; 95:1-6.
76. Clements WD, O'Rourke DM, Rowlands BJ, Ennis M. The role of mast cell activation in cholestatic pruritus. Agents Actions 1994; 41:C30-1.
77. Stahle-Backdahl M. Uremic pruritus: clinical and experimental studies. Acta Dermato-Venereologica (Stockh) 1989; 145:1-38.
78. Szepietowski JC. Selected elements of the pathogenesis of pruritus in hemodialysis patients: my own study. Med Sci Monitor 1996; 2:343-7.
79. Young AW, Sweeny EW, David DS, Cheigh J, Hochgelerent EL, Sakai S. Dermatologic evaluation of pruritus in patients on hemodialysis. NY State J Med 1973; 73:2670-4.
80. Matsumoto M, Ichimam K, Horie A. Pruritus and mast cell proliferation of the skin in end stage renal failure. Clinical Nephrology 1985; 23:285-8.
81. Ponticelli C, Bencini PL. Uremic pruritus: a review. Nephron 1992; 66:1-5.
82. Leong SO, Tann CC, Lye WC, Lee EJ, Chan HL. Dermal mast cell density and pruritus in end-stage renal failure. Ann Acad Med Singapore 1994; 23:327-9.
83. Goicoechea M, deSequera P, Ochando A, Andrea C, Caramelo C. Uremic pruritus: an unresolved problem in hemodialysis patients. Nephron 1999; 82:73-4.
84. Pauli-Magnus C, Mikus G, Alscher DM, Kirschner T, Nagel W, Gugeler N, Risler T, Berger ED, Kuhlman U, Mettang T. Naltrexone does not relieve uremic pruritus. J Am Soc Nephrol 2000; 11:514-9.
85. Urbonas A, Schwartz RA, Szepietowski JC. Uremic pruritus: an update. Am J Nephrol 2001; 21:343-50.
86. Lowman MA, Rees PH, Beynon RC, Church MK. Human mast cell heterogeneity: histamine release from mast cells dispersed from skin, lung adenoids, tonsils, and colon in response to IgE-dependent and non-immunological stimuli. J Allergy Clin Immunol 1988;81:590-7.
87. Szepietowski JC, Thepen T, Szepietowski T, Bihari IC, vanVloten WA. Phenotype analysis of cell infiltrate in normal-looking skin of haemodialysis patients. Acta Dermatovenerological (Croat) 1996; 4:3-6.
88. Mettang T, Pauli-Magnus C. The pathophysiological puzzle of uremic pruritus: insights and speculations from therapeutic and epidemiological studies. Perit Dial Int 2000; 20:493-4.
89. Szepietowski JC, Thepen T, vanVloten WA, Szepietowski T, Bihari IC. Pruritus and mast cell proliferation in the skin of haemodialysis patients. Inflammation Res 1995; 44(Suppl. 1):S84-5.
90. Tsakalos ND, Theoharides TC, Kops SK, Askenase PW. induction of mast cell secretion by parathormone. Biochem Pharmacol 1983; 32:355-60.
91. Blachley JD, Blankenship DM, Menter A, Parker TF, Knochel JP. Uremic pruritus: skin divalent ion content and response to ultraviolet phototherapy. Am J Kidney Dis 1985; 5:236-41.
92. Graf H, Kovarik J, Stummvoll HS, Wolf A. Disappearance of uraemic pruritus after lowering dialysate magnesium concentration. Br Med J 1979; 2:1478-9.
93. Ahmad S. Uremic pruritus. I. Semin Dialysis 1993; 6:348-50.
94. Kyriazis J, Glotsos J. Dialysate calcium concentration of < 1.25 mmol/1: is it effective in suppressing uremic pruritus? Nephron 2000; 84:85-6.
95. Friga V, Linos A, Linos D. Is aluminium toxicity responsible for uremic pruritus in chronic hemodialysis patients? Nephron 1997; 75:48-53.
96. Kumagai H, Utsumi J, Suzuki T. Endogenous opioid system in uraemic patients. Br J Clinical Pharmacology; abstracts of the joint meeting of VII World Conference on Clinical Pharmacology and Therapeutics IUPHAR. 2000:282. [?AUTHOR: should this be Eur J. . .?]
97. Peer G, Kivity S, Agami O, Fireman E, Silverberg D, Blum M, Iaina A. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 1996; 348:1552-4.
98. Cormia FE. Pruritus, an uncommon but important symptom of systemic carcinoma. Arch Dermatol 1965; 92:36-9.
99. Storck H. Cutaneous paraneoplastic syndromes. Medizinische Klinik 1976; 76:356-72.
100. Shoenfeld Y, Weiberger A, Ben-Bassat M, Pinkhas J. Generalized pruritus in metastatic adenocarcinoma of the stomach. Dermatologica 1977; 155:122-4.
101. Andreev VC. Skin manifestations in visceral cancer. Curr Problems Dermatol 1978; 8:4.
102. Beeaff DE. Pruritus as a sign of systemic disease, report of metastatic small cell carcinoma. Arizona Med 1980; 37:831-3.
103. Lober CW. Pruritus and malignancy. Clin Dermatol 1993; 11:125-8.
104. Twycross R. Pruritus and pain in en cuirass breast cancer. In: Twycross R, ed. Pain Relief in Advanced Cancer. Edinburgh, Churchill Livingstone, 1994:209.
105. Rajka G. Investigation of patients suffering from generalized pruritus with special reference to systemic diseases. Acta Dermato-Venereologica (Stockh) 1966; 46:190-4.
106. Fine J. Mastocytosis. Int J Dermatol 1980; 19:117-23.
107. Marney SR. Mast cell disease. Allerg Proceed 1992; 13:303-10.
108. Abdel-Naser MB, Gollnick H, Orfanos CE. Aquagenic pruritus as a presenting symptom of polycythemia vera. Dermatology 1993; 187:130-3.
109. Abel EA, Wood GS, Hoppe RT. Mycosis fungoides: clinical and histological features, staging, evaluation, and approach to treatment. CA Cancer J Clin 1993; 43:93-115.
110. Winkelmann RK, Muller SA. Pruritus. Ann Rev Med 1964; 15:53-64.
111. Botero F. Pruritus as a manifestation of systemic disorders. Cutis 1978; 21:873-80.
112. Hubscher SG, Lumley MA, Elias E. Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin's lymphoma. Hepatology 1993; 17:70-7.
113. Lewiecki MC, Rahmn R. Pruritus, a manifestation of iron deficiency. JAMA 1976; 236:2319-20.
114. Shapiro RS, Samorodin C, Hood AF. Pruritus as a presenting sign of acquired immunodeficiency syndrome. J Am Acad Dermatol 1987; 16:1115-17.
115. Breuer-McHam JN, Marshall GD, Lewis DE, Duvic M. Distinct serum cytokines in AIDS-related skin diseases. Viral Immunol 1998; 11:215-20.
116. Milazzo F, Piconi S, Trabattoni D, Magni C, Coen M, Capetti A, Fusi ML, Parravicini C, Clerici M. Intractable pruritus in HIV infection: immunologic characterization. Allergy 1999; 54:266-72.
117. Hermens JM, Ebertz JM, Hanifin JM, Hirshman CA. Comparison of histamine release in human skin mast cells induced by morphine, fentanyl, and oxymorphone. Anesthesiology 1985; 62:124-9.
118. Saucedo R, Erill S. Morphine-induced skin wheals: a possible model for the study of histamine release. Clin Pharmacol Therapeut 1985; 38:365-70.
119. Ballantyne JC, Loach AB, Carr DB. The incidence of pruritus after epidural morphine. Anaesthesia 1989; 44:863.
120. Woodham M. Pruritus with sublingual buprenorphine. Anaesthesia 1988; 43:806-7.
121. Katcher J, Walsh D. Opioid-induced itching: morphine sulfate and hydromorphone hydrochloride. J Pain Sympt Manage 1999; 17:70-2.
122. Ballantyne JC, Loach AB, Carr DB. Itching after epidural and spinal opiates. Pain 1988; 33:149-60.
123. Kuraishi Y, Yamaguchi T, Miyamoto T. Itch-scratch responses induced by opioids through central mu opioid receptors in mice. J Biomed Sci 2000; 7:248-52.
124. Barke KE, Hough LB. Opiates, mast cells and histamine release. Life Sci 1993; 53:1391-9.
125. Reisine T, Pasternak G. Opioid analgesics and antagonists. In: Hardman J, Goodman G, Limbird L, eds. Goodman and Gilman's Pharmacological Basis of Therapeutics. 9E. London, McGraw-Hill, 1996:521-55.
126. Withington DE, Patrick JA, Reynolds F. Histamine release by morphine and diamorphine in man. Anaesthesia 1993; 48:26-9.
127. Yeh HM, Chen LK, Lin CJ, Chan WH, Chen YP, Lin CS, Sun WZ, Wang MJ, Tsai SK. Prophylactic intravenous ondansetron reduces the incidence of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery. Anesthesia Analgesia 2000; 91:172-5.
128. Koenigstein H. Experimental study of itch in animals. Archives de dermatologie et de syphiligraphie 1948; 57:828-49.
129. Thomas DA, Williams GM, Iwata K, Kenshalo DR, Dubner R. Multiple effects of morphine on facial scratching in monkeys. Anesthesia Analgesia 1993; 77:933-5.
130. Wang SC. Emetic and Antiemetic Drugs. In: Roots W, Hofmann F, eds. Physiological Pharmacology. New York, Academic Press, 1965:255-328.
131. Costello DJ, Borison HL. Naloxone antagonizes narcotic self-blockade of emesis in the cat. J Pharmacol Exp Therapeut 1977; 203:222-30.
132. Okano K, Togashi Y, Umeuchi H. Anti-pruritic effect of opioid kappa receptor agonist TRK-820. Br J Clinical Pharmacology, abstracts of the joint meeting of VII World Conference on Clinical Pharmacology and Therapeutics IUPHAR. 2000:283. [?AUTHOR: should this be Eur J. . .?]
133. Saltzer EJ, Grove G. Relief from uremic patients: a therapeutic approach. Cutis 1975; 16:298-9.
134. Gilchrest BA, Rowe JW, Brown RS, Steinman TI, Arndt KA. Relief of uremic pruritus with ultraviolet phototherapy. N Engl J Med 1997; 297:136-8.
135. Holme SA, Mills CM. Crotamiton and narrow-band UVB phototherapy: novel approaches to alleviate pruritus of breast carcinoma skin infiltration. J Pain Sympt Manage 2001; 22:803-5.
136. Lim HW, Vallurupalli S, Meola T, Soter NA. UVB phototherapy is an effective treatment for pruritus in patients infected with HIV. J Am Acad Dermatol 1997; 37:414-17.
137. Szepietowski JC, Morita A, Tsuji T. Ultraviolet B induces mast cell apoptosis: a hypothetical mechanism of ultraviolet B treatment for uraemic pruritis. Med Hypotheses 2002; 58:167-70.
138. Kumakiri M, Hashimoto K, Willir I. Biological changes of human cutaneous nerves caused by ultraviolet irradiation: An ultrastructural study. Br J Dermatol 1978; 99:65-75.
139. Neuberger J, Jones EA. Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy. Eur J Gastroenterol Hepatol 2001; 13:1393-4.
140. Smith EB, King CA, Baker MD. Crotamiton lotion in pruritus. Int J Dermatol 1984; 23:684-5.
141. Wasik F, Szepietowski J, Szepietowski T, Weyde W. Relief of uraemic pruritus after balneological therapy with a bath oil containing polidocanol (Balneum Hermal Plus). An open clinical study. J Dermatoll Treat 1996; 7:231-3.
142. Vieluf D, Matthies C, Ring J. Dry and itching skin - therapy with a new preparation, containing urea and polidocanol. Zeitschrift fur Hautkrankheiten 1992; 67:816-21.
143. Hauss H, Proppe A, Matthies C. Comparative study of a formulation containing urea and polidocanol and a greasy cream containing linoleic acid in the treatment of dry, pruritic skin lesions. Dermatosen 1993; 41:184-8.
144. Freitag G, Hoppner Th. Results of a postmarketing drug monitoring survey with a polidocanol-urea preparation for dry, itching skin. Curr Med Res Opin 1997; 13:529-37.
145. Breneman DL, Cardone JS, Blumsack RF, Lather RM, Searle EA, Pollack VE. Topical capsaicin for treatment of hemodialysis-related pruritus. J Am Acad Dermatol 1992; 26:91-4.
146. Hahn GS. Strontium is a potent and selective inhibitor of sensory irritation. Dermatol Surg 1999; 25:689-94.
147. Zhai H, Hannon W, Hahn GS, Harper RA, Pelosi A, Maibach HI. Strontium nitrate decreased histamine-induced itch magnitude and duration in man. Dermatology 2000; 200:244-6.
148. Zhai H, Hannon W, Hahn GS, Pelosi A, Harper RA, Maibach HI. Strontium nitrate suppresses chemically-induced sensory irritation in humans. Contact Dermatitis 2000; 42:98-100.
149. Muston H, Felix R, Shuster S. Differential effect of hypnotics and anxiolytics on itch and scratch. J Invest Dermatol 1979; 72:283.
150. Hellier FF. A comparative trial of trimeprazine and amylobarbitone in pruritus. Lancet 1963; 1:471-2.
151. Bleehen SS, Thomas SE, Greaves MW, Newton J, Kennedy CT, Hindley F, Marks R, Hazell M, Rowell NR, Fairiss GM. Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomized double-blind study. Br J Dermatol 1987; 117:81-8.
152. Aymard JP, Lederlin P, Witz F, Colomb JN, Herbeuval R, Weber B. Cimetidine for pruritus in Hodgkin's disease. Br Med J 1980; 280:151-2.
153. Weick JK, Donovan PB, Najean Y, Dresch C, Pisciotta AV, Cooperberg AA, Goldberg JD. The use of cimetidine for the treatment of pruritus in polycythemia vera. Arch Intern Med 1982; 142:241-2.
154. 2-receptor antagonists. Clin Pharmacol Therapeut 1999; 65:369-76.
155. Richelson E. Antimuscarinic and other receptor-blocking properties of antidepressants. Mayo Clinic Proc 1983; 58:40-6.
156. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F. Mechanism of action of doxepin in the treatment of chronic urticaria. Fundament Clin Pharmacol 1990; 4:147-58.
157. 1 receptors of guinea pig ileum. Eur J Pharmacol 1979; 59:479-83.
158. 2 in human skin. Br J Dermatol. 1997; 137:386-90.
159. Drake LA, Fallon JD, Sober A. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group. J Am Acad Dermatol 1994; 31:613-16.
160. Breneman DL, Dunlap EE, Monroe EW. Doxepin cream relieves eczema-associated pruritus within 15 minutes and is not accompanied by a risk of rebound upon discontinuation. J Dermatol Treat 1997; 8:161-8.
161. Anonymous. Doxepin cream for eczema? Drug Therapeut Bull 2000; 38:31.
162. Smith PF, Corelli RL. Doxepin in the management of pruritus associated with allergic cutaneous reactions. Ann Pharmacother 1997; 31:633-5.
163. Raderer M, Muller C, Scheithauer W. Ondansetron for cholestatic jaundice due to cholestasis. N Engl J Med 1994; 300:1540.
164. 3) receptor antagonists: effectivenss of ondansetron. Pain 1995; 61:33-7.
165. Quigley C, Plowman PN. 5HT3 receptor antagonists and pruritus due to cholestasis. Palliat Med 1996; 10:54.
166. Balaskas EV, Bamihas GI, Karamouzis M, Voyiatzis G, Tourkantonis A. Histamine and serotonin in uremic pruritus: effect of ondansetron in CAPD-pruritic patients. Nephron 1998; 78:395-402.
167. O'Donohue JW, Haigh C, Williams R. Ondansetron in the treatment of pruritus of cholestasis: a randomised controlled trial. Gastroenterology 1997; 112:A1349.
168. Murphy M, Reaich D, Pai P, Finn P, Carmichael AJ. A randomised, placebo-controlled, double-blind trial of ondansetron in renal itch. Br J Dermatol 2001; 145(Suppl. 59):20-1.
169. Muller C, Pongratz S, Pidlich J, Penner E, Kaider A, Schemper M, Raderer M, Scheithauer W, Ferenci P. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998; 10:865-70.
170. Zylicz Z, Smits C, Chem D, Krajnik M. Paroxetine for pruritus in advanced cancer. J Pain Sympt Manage 1998; 16:121-4.
171. Bergeron R, Blier P. Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. Am J Psychiat 1994; 151:1084-6.
172. Krajnik M, Zylicz Z. Understanding pruritus in systemic disease. J Pain Sympt Manage 2001; 21:151-68.
173. deBoer T. The effects of mirtazaine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 1995; 10:19-24.
174. Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int Clin Res 1995; 10:25-36.
175. Davis MP, Frandsen JL, Walsh D, Andresen S, Taylor S. Mirtazapine for pruritus. in press.[AUTHOR: journal?]
176. Metze D, Reimann S, Beissert S, Luger TA. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol 1999; 41:533-9.
177. Carson KL, Tran TT, Cotton P, Sharara AI, Hunt CM. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol 1996; 91:1022-3.
178. Wolfhagen FHJ, Sternieri E, Hop WCJ, Vitale G, Bertolotti M, vanBuuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997; 113:1264-9.
179. Mitchell JE. Naltrexone and hepatotoxicity. Lancet 1986; 1:1215.
180. Zylicz Z, Krajnik M. Codeine for pruritus in primary biliary cirrhosis. Lancet 1999; 353:813.
181. Juby LD, Wong VS, Losowsky MS. Buprenorphine and hepatic pruritus. Br J Clin Pract 1994; 48:331.
182. Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin: results of a double-blind crossover randomized trial. Gastroenterology 1988; 94:488-93.
183. Anwer MS, Kroker R, Hegner D. Inhibition of hepatic uptake of bile acids by rifamycins. Naunyn Schmiedebergs Arch Pharmacol 1978; 302:19-24.
184. Bachs L, Pares A, Elena M, Piera C, Rodes J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989; 1:574-6.
185. Bloomer JR, Boyer JL. Phenobarbital effects in cholestatic liver disease. Ann Intern Med 1975; 82:310-17.
186. Carey JB. Lowering of serum bile acid concentrations and relief of pruritus in jaundiced patients fed a bile acid sequestering resin. J Lab Clin Med 1960; 56:797-8.
187. Datta DV, Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology 1966; 50:323-32.
188. Sherlock S, Dooley J. Diseases of the Liver and Biliary System, 9th edn. Oxford, Blackwell Scientific, 1993.
189. Ahrens EH, Payne MA, Kunkel HG. Primary biliary cirrhosis. Medicine 1950; 29:299-364.
190. Lloyd-Thomas HGL, Sherlock S. Testosterone therapy for the pruritus of obstructive jaundice. Br Med J 1952; ii:1289-91.
191. Sherlock S. Diseases of the Liver and Biliary System, 6th edn. Oxford, Blackwell Scientific, 1981.
192. Welder AA, Robertson JW, Melchert RB. Toxic effects of anabolic-androgen steroids in primary rat hepatic cell cultures. J Pharmacol Toxicol Methods 1995; 33:187-95.
193. Gurakar A, Caraceni P, Fagiuoli S, vanThiel DH. Androgenic/anabolic steroid-induced intrahepatic cholestasis: a review with four additional case reports. J Oklahoma State Med Assoc 1994; 87:399-404.
194. Massry SG, Popovtzer MM, Coburn JW, Makoff DL, Maxwell MH, Kleeman CR. Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia. New England J Medicine 1968; 279:697-700.
195. Gilchrest BA, Rowe JW, Brown RS. Ultraviolet phototherapy of uremic pruritus: long-term results and possible mechanisms of action. Annals of Internal Medicine 1979; 91:17-21.
196. Silva SR, Viana PC, Lugon NV, Hoette M, Ruzany F, Lugon JR. Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron 1994; 67:270-3.
197. Finelli C, Gugliotta L, Gamberi B, Vianelli N, Visani G, Tura S. Relief of intractable pruritus in polycythemia vera with recombinant interferon alpha. Am J Hematology 1993; 43:316-8.
198. Tefferi A, Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood 2002; 99:2627.
199. Fjellner B, Hagermark O. Pruritus in polycythemia vera: treatment with aspirin and possibility of platelet involvement. Acta Dermato-Venereologica (Stockh) 1979; 59:505-12.
200. Gobbi PG, Attardo-Parrinello G, Lattanzio G, Rizzo SC, Ascari E. Severe pruritus should be a B-symptom in Hodgkin's disease. Cancer 1983; 51:1934-6.
201. Asokumar B, Newman LM, McCarthy RJ, Ivankovitch AD, Tuman KJ. Intrathecal bupivacaine reduces pruritus and prolongs duration of fentanyl analgesia during labor: a prospective, randomized, controlled trial. Anaesthesia and Analgesia 1998; 87:1309-15.
202. Korbon GA, James DJ, Verlander JM, DiFazio CA, Rosenbaum SM, Levy SJ, Perry PC. Intramuscular naloxone reverses the side effects of epidural morphine while preserving analgesia. Regional Anaesthesia 1985; 10:16-20.
203. Cohen SE, Ratner EF, Kreitzman TR, Archer JH, Mignano LR. Nalbuphine is better than naloxone for treatment of side effects after epidural morphine. Anesthesia and Analgesia 1992; 75:747-52.
204. Ueyama H, Nishimura M, Tashiro C. Naloxone reversal of nystagmus associated with intrathecal morphine administration (letter). Anesthesiology 1992; 76:153.
205. Kjellberg F, Tramer MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. European J Anaesthesiology 2001; 18:346-57.
206. Dunteman E, Karanikolas M. Transnasal butorphanol for the treatment of opioid-induced pruritus unresponsive to antihistamines. J Pain and Symptom Management 1996; 12:255-60.
207. Gunter JB, McAuliffe J, Gregg T, Weidner N, Varughese AM, Sweeney DM. Continuous epidural butorphanol relieves pruritus associated with epidural morphine infusions in children. Paediatric Anaesthesia 2000; 10:167-72.
208. Bernstein JE, Grinzi RA. Butorphanol-induced pruritus antagonised by naloxone. J the Am Academy of Dermatology 1981; 5:227-8.
209. Borgeat A, Wilder-Smith OHG, Saiah M, Rifat K. Subhypnotic doses of propofol relieve pruritus induced by epidural and intrathecal morphine. Anesthesiology 1992; 76:510-2.
210. Colbert S, O'Hanlon DM, Galvin S, Chambers F, Moriarty DC. The effect of rectal diclofenac on pruritus in patients receiving intrathecal morphine. Anaesthesia 1999; 54:948-52.
211. Colbert S, O'Hanlon DM, Chambers F, Moriarty DC. The effect of intravenous tenoxicam on pruritus in patients receiving epidural fentanyl. Anaesthesia 1999; 54:76-80.